Quanterix downgraded by Canaccord Genuity with a new price target
$QTRX
Biotechnology: Laboratory Analytical Instruments
Industrials
Canaccord Genuity downgraded Quanterix from Buy to Hold and set a new price target of $5.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2025 | $5.00 | Buy → Hold | Canaccord Genuity |
| 2/1/2024 | $30.00 | Sector Outperform | Scotiabank |
| 9/25/2023 | $25.00 → $32.00 | Hold → Buy | Canaccord Genuity |
| 8/8/2023 | $30.00 | Market Perform → Outperform | SVB Securities |
| 5/23/2023 | $13.00 → $27.00 | Neutral → Buy | Goldman |
| 8/15/2022 | $40.00 → $12.00 | Buy → Hold | Canaccord Genuity |
| 8/9/2022 | $38.00 → $18.00 | Outperform → Market Perform | Cowen |
| 8/9/2022 | $35.00 → $15.00 | Outperform → Mkt Perform | SVB Leerink |
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15, 2026, inducement grants (the "Inducement Grants") were made to three employees in connection with the commencement of their employment. The Inducement Grants consisted of 336,804 restricted stock units ("RSUs") representing 336,804 shares of Quanterix common stock. The RSUs vest in four equal installments on the first four anniversaries of the grant date, subject to the applicable individual's continued employment with the Company or one of its subsidiaries through the vesting date. T
Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company's new Chief Financial Officer, effective June 22. Faessler brings extensive finance leadership experience and expertise in managing complex organizations in the life science tools industry, positioning him to play a pivotal role in executing Quanterix's strategic growth plans in the coming years. "We are thrilled to welcome Jason to the Quanterix leadership team," said Everett Cunningham, Chief Executive Officer of Quanterix. "His extensive track record within life science organization
Strategic Leadership Addition Signals Drive to Expand Diagnostics Business Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. This strategic hire underscores Quanterix's commitment to transforming its Diagnostics opportunity into a key component of the company's future growth strategy. Starting with Alzheimer's Disease Diagnostics, Albrecht will lead the company's Diagnostics strategy and the development of a comprehensive infrastructure and operational framework necessary to scale Quante
8-K - Quanterix Corp (0001503274) (Filer)
8-K - Quanterix Corp (0001503274) (Filer)
8-K - Quanterix Corp (0001503274) (Filer)
4 - Quanterix Corp (0001503274) (Issuer)
3 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
Canaccord Genuity downgraded Quanterix from Buy to Hold and set a new price target of $5.00
Scotiabank initiated coverage of Quanterix with a rating of Sector Outperform and set a new price target of $30.00
Canaccord Genuity upgraded Quanterix from Hold to Buy and set a new price target of $32.00 from $25.00 previously
Reports $36.4 million in revenue and approximately $103 million of cash and marketable securities Company prioritizing product roadmap and investing in initiatives to drive commercial effectiveness Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the first quarter ended March 31, 2026. "We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we have captured the cost synergies from the Akoya acquisition," said Everett Cunningham, President & CEO of Quanterix. "As part of this process, we are focusing our
Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. E.T., to discuss its first quarter 2026 financial results. Quanterix will issue a press release regarding its first quarter 2026 financial results prior to the conference call on Wednesday, May 6, 2026, after the market closes. The press release will be posted on the Quanterix website at http://www.quanterix.com/. In conjunction with this announcement, the Company will host a conference call on May 6, 2026, at 4:30 PM ET. The dial-in number for USA & Canada
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the "Company"), today announced that the Company's 2026 annual meeting of shareholders (the "Annual Meeting") will be held virtually, by means of remote communication, on Tuesday, June 9, 2026 at 10:00 am Eastern Time. Stockholders of record of the Company's common stock as of the close of business on April 14, 2026 will be entitled to vote at the Annual Meeting. Additional information regarding the Annual Meeting will be provided in the Company's proxy statement. Because the date of the Annual Meeting has been advanced by more than thirty (30) days from the anniversary
SC 13G/A - Quanterix Corp (0001503274) (Subject)
SC 13G - Quanterix Corp (0001503274) (Subject)
SC 13G/A - Quanterix Corp (0001503274) (Subject)
Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company's new Chief Financial Officer, effective June 22. Faessler brings extensive finance leadership experience and expertise in managing complex organizations in the life science tools industry, positioning him to play a pivotal role in executing Quanterix's strategic growth plans in the coming years. "We are thrilled to welcome Jason to the Quanterix leadership team," said Everett Cunningham, Chief Executive Officer of Quanterix. "His extensive track record within life science organization
Strategic Leadership Addition Signals Drive to Expand Diagnostics Business Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. This strategic hire underscores Quanterix's commitment to transforming its Diagnostics opportunity into a key component of the company's future growth strategy. Starting with Alzheimer's Disease Diagnostics, Albrecht will lead the company's Diagnostics strategy and the development of a comprehensive infrastructure and operational framework necessary to scale Quante
Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham